Regarding: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: Bevacizumab in combination with interferon-α2a compared with sunitinib

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1196-1197
Number of pages2
JournalBritish Journal of Cancer
Issue number7
Publication statusPublished - Mar 2010

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this